CAMBRIDGE, Mass.– Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, announced that its Board of Directors has begun a strategic review of options for Livechain Inc. (OTCID: LICH), where Vyome holds a 70 percent controlling interest.
“We are committed to our shareholders and maximizing shareholder value,” said Krishna Gupta, Chairman of Vyome. “Most of our shareholders are probably completely unaware that we are a 70 percent controlling shareholder of LICH; we are keen to explore all ways to create value from this asset. At this point, the Board has not formed an opinion as to the best path for Livechain, but we intend to spend the next month reviewing the costs and benefits of our options, which could include launching a new business, forming a crypto treasury, merging with an existing business, or an outright sale.”
Vyome acquired its stake in Livechain in 2021 with the goal of establishing a viable publicly held business through an OTC listing. With Vyome itself now listed on Nasdaq, the company is weighing new possibilities.
“Vyome originally purchased a controlling interest in LICH in 2021 with the intention of potentially listing on the OTC to establish a viable publicly held business. With Vyome now trading on Nasdaq, there is an opportunity to look at other creative options for LICH,” said Venkat Nelabhotla, CEO of Vyome.
